CA2874253A1 - 7-oxo-4,7-dihydro-pyrazolo [1,5-a] pyrimidine derivatives which are useful in the treatment, amelioration or prevention of a viral disease - Google Patents

7-oxo-4,7-dihydro-pyrazolo [1,5-a] pyrimidine derivatives which are useful in the treatment, amelioration or prevention of a viral disease Download PDF

Info

Publication number
CA2874253A1
CA2874253A1 CA2874253A CA2874253A CA2874253A1 CA 2874253 A1 CA2874253 A1 CA 2874253A1 CA 2874253 A CA2874253 A CA 2874253A CA 2874253 A CA2874253 A CA 2874253A CA 2874253 A1 CA2874253 A1 CA 2874253A1
Authority
CA
Canada
Prior art keywords
optionally substituted
alkyl
compound
optionally
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2874253A
Other languages
English (en)
French (fr)
Inventor
Andrea Wolkerstorfer
Oliver Szolar
Norbert Handler
Stephen Cusack
Thibault Sauvaitre
Celine Michaut-Simon
Christophe Morice
Bruno Giethlen
Thierry Langer
Mark Smith
Sung-Sau So
Dirk Classen-Houben
Helmut Buschmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Savira Pharmaceuticals GmbH
F Hoffmann La Roche AG
Europaisches Laboratorium fuer Molekularbiologie EMBL
Original Assignee
Savira Pharmaceuticals GmbH
F Hoffmann La Roche AG
Europaisches Laboratorium fuer Molekularbiologie EMBL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savira Pharmaceuticals GmbH, F Hoffmann La Roche AG, Europaisches Laboratorium fuer Molekularbiologie EMBL filed Critical Savira Pharmaceuticals GmbH
Publication of CA2874253A1 publication Critical patent/CA2874253A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2874253A 2012-05-23 2013-05-23 7-oxo-4,7-dihydro-pyrazolo [1,5-a] pyrimidine derivatives which are useful in the treatment, amelioration or prevention of a viral disease Abandoned CA2874253A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261650725P 2012-05-23 2012-05-23
US61/650,725 2012-05-23
PCT/EP2013/060634 WO2013174931A1 (en) 2012-05-23 2013-05-23 7-oxo-4,7 -dihydro- pyrazolo [1, 5 -a] pyrimidine derivatives which are useful in the treatment, amelioration or prevention of a viral disease

Publications (1)

Publication Number Publication Date
CA2874253A1 true CA2874253A1 (en) 2013-11-28

Family

ID=48669866

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2874253A Abandoned CA2874253A1 (en) 2012-05-23 2013-05-23 7-oxo-4,7-dihydro-pyrazolo [1,5-a] pyrimidine derivatives which are useful in the treatment, amelioration or prevention of a viral disease

Country Status (11)

Country Link
US (2) US20130317021A1 (Direct)
EP (1) EP2861232A1 (Direct)
JP (1) JP2015521189A (Direct)
KR (1) KR20150014506A (Direct)
CN (1) CN104507481B (Direct)
BR (1) BR112014029006A2 (Direct)
CA (1) CA2874253A1 (Direct)
HK (1) HK1204987A1 (Direct)
MX (1) MX2014014109A (Direct)
RU (1) RU2014146778A (Direct)
WO (1) WO2013174931A1 (Direct)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2723746A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
JP2015517555A (ja) * 2012-05-23 2015-06-22 ザヴィラ ファーマシューティカルズ ゲーエムベーハー ７−オキソ−チアゾロピリジン炭酸誘導体及びウイルス性疾患の治療、改善又は予防におけるその使用
HK1209746A1 (en) 2012-12-07 2016-04-08 沃泰克斯药物股份有限公司 Compounds useful as inhibitors of atr kinase
CA2904760A1 (en) 2013-03-13 2014-09-18 Genentech, Inc. Pyrazolo compounds and uses thereof
JP2016512239A (ja) 2013-03-15 2016-04-25 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物
JP2016512815A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
US8969360B2 (en) 2013-03-15 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
ES2768678T3 (es) 2013-12-06 2020-06-23 Vertex Pharma Compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de la ATR quinasa, su preparación, diferentes formas sólidas y derivados radiomarcados de las mismas
HRP20200186T1 (hr) 2014-06-05 2020-05-29 Vertex Pharmaceuticals Inc. Radioaktivno obilježeni derivati 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-karboksamid spojeva koji se koriste kao inhibitori atr kinaze, priprava navedenih spojeva i njihovi različiti čvrsti oblici
PT3157566T (pt) 2014-06-17 2019-07-11 Vertex Pharma Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr
WO2016003929A1 (en) 2014-07-01 2016-01-07 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN107074880A (zh) 2014-07-07 2017-08-18 萨维拉制药有限公司 二氢吡啶并吡嗪‑1,8‑二酮和它们在治疗、改善或预防病毒疾病中的用途
ES2857906T3 (es) 2015-04-28 2021-09-29 Shionogi & Co Derivado de piridona policíclica contra la influenza y profármaco del mismo
US20170081331A1 (en) 2015-09-18 2017-03-23 F. Hoffmann-La Roche Ag Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease
HK1258570A1 (zh) 2015-09-30 2019-11-15 Vertex Pharmaceuticals Inc. 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
SG10201911957QA (en) 2015-12-15 2020-02-27 Shionogi & Co Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
CN109415345B (zh) 2016-06-29 2022-01-11 豪夫迈·罗氏有限公司 基于哒嗪酮的广谱抗流感抑制剂
EP4458348A3 (en) 2016-08-10 2025-01-29 Shionogi & Co., Ltd Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
EP3525786A4 (en) * 2016-10-12 2020-03-18 Merck Sharp & Dohme Corp. KDM5 INHIBITORS
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
TW201920185A (zh) 2017-09-15 2019-06-01 美商艾杜諾生物科技公司 吡唑并嘧啶酮化合物及其用途
MX2020008061A (es) * 2018-01-31 2020-09-09 Janssen Sciences Ireland Unlimited Co Pirazolopirimidinas sustituidas con cicloalquilo que tienen actividad contra vrs.
CN113620977B (zh) * 2021-08-24 2024-02-02 江苏弘和药物研发有限公司 一种噻唑烷并嘧啶酮乙酸的合成方法
CN117304133A (zh) * 2023-09-26 2023-12-29 华南农业大学 一种具有噻唑侧链的截短侧耳素衍生物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475109A (en) 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
US6559145B2 (en) * 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
CA2487211C (en) * 2002-06-04 2010-09-14 Neogenesis Pharmaceuticals, Inc. Pyrazolo(1,5a) pyrimidine compounds as antiviral agents
EP1790638B1 (en) 2004-09-15 2013-04-03 Shionogi Co., Ltd. Carbamoylpyridone derivative having hiv integrase inhibitory activity
TW200716632A (en) 2005-05-16 2007-05-01 Gilead Sciences Inc Integrase inhibitor compounds
WO2007146813A2 (en) * 2006-06-08 2007-12-21 Cylene Pharmaceuticals, Inc. Pyridinone analogs as cell proliferation inhibitors
EP2412708A4 (en) 2009-03-26 2014-07-23 Shionogi & Co SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
WO2011000566A2 (en) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
CN101671336B (zh) * 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
JP2015517555A (ja) * 2012-05-23 2015-06-22 ザヴィラ ファーマシューティカルズ ゲーエムベーハー ７−オキソ−チアゾロピリジン炭酸誘導体及びウイルス性疾患の治療、改善又は予防におけるその使用

Also Published As

Publication number Publication date
JP2015521189A (ja) 2015-07-27
KR20150014506A (ko) 2015-02-06
CN104507481B (zh) 2017-08-04
US20130317021A1 (en) 2013-11-28
CN104507481A (zh) 2015-04-08
WO2013174931A1 (en) 2013-11-28
HK1204987A1 (en) 2015-12-11
US20160367557A1 (en) 2016-12-22
BR112014029006A2 (pt) 2017-06-27
MX2014014109A (es) 2016-03-31
RU2014146778A (ru) 2016-07-10
EP2861232A1 (en) 2015-04-22

Similar Documents

Publication Publication Date Title
EP2864338B1 (en) 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
CA2874253A1 (en) 7-oxo-4,7-dihydro-pyrazolo [1,5-a] pyrimidine derivatives which are useful in the treatment, amelioration or prevention of a viral disease
US8921388B2 (en) Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
EP2794616B1 (en) Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
US8952039B2 (en) Pyridone derivatives and their use in the treatment, ameloriation or prevention of a viral disease
WO2016005330A1 (en) Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases
US9505758B2 (en) Substituted 1,5-naphthyridines as endonuclease inhibitors
WO2017046318A1 (en) Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease
WO2017046362A1 (en) Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease
EP3166943A1 (en) Pyridopyrazine compounds and their use in the treatment, amelioration or prevention of influenza
HK1205128B (en) 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
HK1199881B (en) Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190523